INNOCARE (688428.SH): Apremilast treatment for systemic lupus erythematosus reaches Phase IIb study primary endpoint.

INNOCARE (688428.SH) announced that the Phase IIb clinical study of the company's independently developed BTK inhibitor, obutinib, for the treatment of systemic lupus erythematosus (SLE) has achieved its main endpoint, and has received approval from the National Medical Products Administration (NMPA) Drug Evaluation Center (CDE) to conduct a Phase III clinical trial. The company will soon initiate this clinical study. The Phase IIb results show that after 48 weeks of treatment, obutinib demonstrated excellent efficacy, good tolerability, and safety in patients.